Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 601–700 of 2,517
Fitzgerald, A. L., Osman, A. A., Xie, T.-X., Patel, A., Skinner, H., Sandulache, V, & Myers, J. N. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.44 · Cited by 83
Blanden, A. R., Yu, X., Loh, S. N., Levine, A. J., & Carpizo, D. R. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.006 · Cited by 83
Walerych, D., Olszewski, M. B., Gutkowska, M., Helwak, A., Żylicz, M., & Żylicz, M. (2009) · Oncogene · doi:10.1038/onc.2009.281 · Cited by 82
“, 2007), and are known to cause additional destabilization of its structure (‘structural mutants’) and/or directly disrupt its DNA contact (‘contact mutants’) (Cho et al., 1994; Bullock et al., 2000).”
BackgroundSer392 Phosphorylation Regulates the Oncogenic Function of Mutant p53
Yap, D. B. S., Hsieh, J.-K., Zhong, S., Heath, V., Gusterson, B., Crook, T., & Lu, X. (2004) · Cancer Research · doi:10.1158/0008-5472.can-1305-2 · Cited by 82
“Hence, mutations at codons 175 and 248 disrupt the conformation of p53 and make it incapable of binding DNA, activating transcription, or inducing apoptosis (5).”
BackgroundSantiago, A., Li, D., Zhao, L., Godsey, A. C., & Liao, D. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e12-10-0771 · Cited by 98
“Of interest, mutations within the DNA-binding domain (DBD, or core domain) of p53 exhibited differential effects on the p53-CRM1 interaction.”
BackgroundStudies of temperature-dependent electronic transduction on DNA hairpin loop sensor
Mao, Y. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng108 · Cited by 83
“We selected segments of 16 nt as target sequences extracted from the human gene for the p53 tumor suppressor (26).”
MethodPrognostic Significance of p53 Codon 72 Polymorphism Differs with Race in Colorectal Adenocarcinoma
Katkoori, V. R., Xu, J., Shanmugam, C., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1719 · Cited by 83
Diet activity, and lifestyle associations with p53 mutations in colon tumors.
Slattery, M. L., Curtin, K. P., Ma, K., Edwards, S. L., Schaffer, D., Anderson, K., & Samowitz, W. S. (2002) · PubMed · Cited by 83
Multisite aggregation of p53 and implications for drug rescue
Wang, G., & Fersht, A. R. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700308114 · Cited by 54
“Brinckerhoff LH, et al. (1999) Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: Implications for peptide vaccines.”
BackgroundStructure and function of DNA-binding proteins
Nelson, H. C. M. (1995) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(95)80006-9 · Cited by 98
Enemark, E. J., Chen, G. L., Vaughn, D. E., Stenlund, A., & Joshua‐Tor, L. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00016-x · Cited by 89
p53 Suppresses the c-Myb-induced Activation of Heat Shock Transcription Factor 3
Tanikawa, J., Ichikawa-Iwata, E., Kanei‐Ishii, C., Nakai, A., Matsuzawa, S., Reed, J. C., & Ishii, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000372200 · Cited by 86
Shi, S. T., Yang, G., Wang, L. D., Xue, Z., Feng, B., Ding, W., Xing, E. P., & Yang, C. S. (1999) · Carcinogenesis · doi:10.1093/carcin/20.4.591 · Cited by 82
The Li-Fraumeni syndrome: An inherited susceptibility to cancer
Evans, S. C., & Lozano, G. (1997) · Molecular Medicine Today · doi:10.1016/s1357-4310(97)01105-2 · Cited by 101
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
Sjöström, J., BLOMQVIST, C. P., Heikkilä, P., von Boguslawski, K., Räisänen-Sokolowski, A. K., Bengtsson, N. O., Mjaaland, I., Malmström, P., Ostenstadt, B., Bergh, J. C. S., et al. (2000) · PubMed · Cited by 83
Lonely No More: p53 Finds Its Kin in a Tumor Suppressor Haven
Oren, M. (1997) · Cell · doi:10.1016/s0092-8674(00)80347-5 · Cited by 89
“Howies (Cho et al., 1994), but also by the fact that they areever, p53 repeatedly defied these expectations: all atmajor hot spots for mutation in human cancer.”
BackgroundA direct effect of activated human p53 on nuclear DNA replication.
Cox, L. S., Hupp, T. R., Midgley, C., & Lane, D. P. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07201.x · Cited by 90
Biochemical and Structural Studies of ASPP Proteins Reveal Differential Binding to p53, p63, and p73
Robinson, R. A., Lü, X., Jones, E. Y., & Siebold, C. (2008) · Structure · doi:10.1016/j.str.2007.11.012 · Cited by 95
“Most p53 mutations map to the DNA-binding domain, they are therefore unable to activate genes upregulated by wild-type p53, a loss of function that ultimately results in unchecked cell division ( Cho et al., 1994 ).”
BackgroundLaptenko, O., Tong, D. R., Manfredi, J., & Prives, C. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.08.011 · Cited by 82
Berardi, M. J., Sun, C. C., Zehr, M., Abildgaard, F., Peng, J. W., Speck, N. A., & Bushweller, J. H. (1999) · Structure · doi:10.1016/s0969-2126(00)80058-1 · Cited by 90
Metallothionein: A Multifunctional Protein from Toxicity to Cancer
Theocharis, S. E., Margeli, A. P., & Koutselinis, A. S. (2003) · The International Journal of Biological Markers · doi:10.1177/172460080301800302 · Cited by 82
Modulation of Binding of DNA to the C-Terminal Domain of p53 by Acetylation
Friedler, A., Veprintsev, D. B., Freund, S. M. V., von Glos, K. I., & Fersht, A. R. (2005) · Structure · doi:10.1016/j.str.2005.01.020 · Cited by 81
Bending and Torsional Flexibility of G/C-rich Sequences as Determined by Cyclization Assays
Dlakić, M., & Harrington, R. E. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.50.29945 · Cited by 81
Molecularly targeted therapies for p53-mutant cancers
Zhao, D., Tahaney, W. M., Mazumdar, A., Savage, M. I., & Brown, P. H. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2575-0 · Cited by 87
“Conformational mutations of p53 disrupt the structure of p53 and abolish DNA-binding ability, while DNA contact mutants alter amino acids that directly bind DNA [19, 20].”
Zhang, H., Xu, J., Long, Y., Maimaitijiang, A., Su, Z., Li, W., & Li, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312928 · Cited by 108
“( D ) The illustration depicts the p53 tetramer binding to DNA magenta, green, yellow and red colors represent the DBDs of individual p53 monomers, derived from PDB:3KMD [24].”
Chen, Y., Zhang, X., Dantas Machado, A. C., Ding, Y., Chen, Z., Qin, P. Z., Rohs, R., & Chen, L. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt584 · Cited by 78
p53--An Acrobat in Tumorigenesis
Moll, U. M., & Schramm, L. (1998) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/10454411980090010101 · Cited by 93
Menendez, D., Inga, A., & Resnick, M. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2297-2308.2006 · Cited by 81
“(8, 36, 61), had little impact on these biological end points.”
BackgroundHormonal Regulation of the p53 Tumor Suppressor Protein in T47D Human Breast Carcinoma Cell Line
Hurd, C., Khattree, N., Alban, P., Nag, K., Jhanwar, S. C., Dinda, S., & Moudgil, V. K. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.48.28507 · Cited by 78
Complex formation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor
Ishido, S., & Hotta, H. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01312-x · Cited by 96
p53 and Brain Tumors: From Gene Mutations to Gene Therapy
Fulci, G., Ishii, N., & Van Meir, E. G. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00187.x · Cited by 79
Structural trees for protein superfamilies
Efimov, A. V. (1997) · Proteins Structure Function and Bioinformatics · doi:10.1002/(sici)1097-0134(199706)28:2<241::aid-prot12>3.0.co;2-i · Cited by 86
Degtjarik, O., Golovenko, D., Diskin-Posner, Y., Abrahmsén, L., Rozenberg, H., & Shakked, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-27142-6 · Cited by 78
The Mdm network and its regulation of p53 activities: a rheostat of cancer risk
Eischen, C. M., & Lozano, G. (2014) · Human Mutation · doi:10.1002/humu.22524 · Cited by 79
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding [Cho et al., 1994].”
BackgroundThe DNA Binding Activity of p53 Displays Reaction-Diffusion Kinetics
Hinow, P., Rogers, C. E., Barbieri, C. E., Pietenpol, J. A., Kenworthy, A. K., & DiBenedetto, E. (2006) · Biophysical Journal · doi:10.1529/biophysj.105.078303 · Cited by 81
Zhang, Y., Yan, W., & Chen, X. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.214585 · Cited by 80
Göhler, T., Reimann, M., Cherny, D., Walter, K., Warnecke, G., Kim, E., & Deppert, W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202344200 · Cited by 80
Mutants TP53 p.R273H and p.R273C but not p.R273G Enhance Cancer Cell Malignancy
Li, J., Yang, L., Gaur, S., Zhang, K., Wu, X., Yuan, Y., Li, H., Hu, S., Weng, Y., & Yen, Y. (2014) · Human Mutation · doi:10.1002/humu.22528 · Cited by 83
“The wt TP53 core domain in complex with DNA was taken from the X-ray crystallographic structure coded as 1TSR [Cho et al., 1994] in the Protein Data Bank.”
Methodp53 in Tumor Progression: Life, Death, and Everything
Mowat, M. R. A. (1998) · Advances in cancer research · doi:10.1016/s0065-230x(08)60764-2 · Cited by 85
Cobbs, C., Samanta, M., Harkins, L. E., Gillespie, G. Y., Merrick, B. A., & MacMillan-Crow, L. A. (2001) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2001.2540 · Cited by 80
Recognition of DNA by p53 Core Domain and Location of Intermolecular Contacts of Cooperative Binding
Rippin, T. M., Freund, S. M. V., Veprintsev, D. B., & Fersht, A. R. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00326-1 · Cited by 76
Reviving the guardian of the genome: Small molecule activators of p53
Nguyen, D., Liao, W., Zeng, S. X., & Lu, H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.013 · Cited by 79
“residues, of which four (Cys182, Cys229, Cys242, and Cys277) are exposed on the surface in wild-type conformation (Cho et al., 1994).”
BackgroundThe roles of TET family proteins in development and stem cells
Yang, J., Bashkenova, N., Zang, R., Huang, X., & Wang, J. (2020) · Development · doi:10.1242/dev.183129 · Cited by 87
“These methylcytosine derivatives can be processed to cytosine through thymine DNA glycosylase (TDG) and a base excision repair (BER) mechanism (Cortellino et al., 2011; He et al., 2011).”
BackgroundA p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo
Bell, H. S., Dufès, C., O’Prey, J., Crighton, D., Bergamaschi, D., Lü, X., Schätzlein, A. G., Vousden, K. H., & Ryan, K. M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28920 · Cited by 88
“Because these 2 evolutionarily conserved boxes are juxtaposed in the crystal structure of the p53 core domain (17), we tested whether the intervening sequence between the boxes could be removed without affecting the ability of the peptide to induce cell death.”
BackgroundGrønbæk, K., Brown, P. D. N., Møller, M. B., Nedergaard, T., Ralfkiaer, E. M., Mӧller, P., Zeuthen, J., & Guldberg, P. (2000) · Leukemia · doi:10.1038/sj.leu.2401901 · Cited by 86
Herndon, J. E., Fleishman, S., Kornblith, A. B., Kosty, M., Green, M. R., & Holland, J. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990115)85:2<333::aid-cncr10>3.0.co;2-q · Cited by 193
Shin, T. H., Paterson, A. J., & Kudlow, J. E. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.9.4694 · Cited by 78
“These divalent p53-responsive elements confer binding of a homotetrameric complex of p53 (4, 12, 15).”
Mechanical Unfoldons as Building Blocks of Maltose-binding Protein
Bertz, M., & Rief, M. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.02.025 · Cited by 82
Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients
Alsner, J., Yilmaz, M. K., Guldberg, P., Hansen, L. L., & Overgaard, J. (2000) · Breast Cancer Research · doi:10.1186/bcr109 · Cited by 79
Wild, C. P., Ridanpää, M., Anttila, S. L., Lubin, R., Soussi, T., Husgafvel‐Pursiainen, K., & Vainio, H. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640306 · Cited by 78
The DNA-binding domain mediates both nuclear and cytosolic functions of p53
Follis, A. V., Llambi, F., Ou, L., Baran, K., Green, D. R., & Kriwacki, R. W. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2829 · Cited by 80
Marcel, V., Vijayakumar, V., Fernandez‐Cuesta, L., Hafsi, H., Sagne, C., Hautefeuille, A. H., Olivier, M., & Hainaut, P. L. (2010) · Oncogene · doi:10.1038/onc.2010.26 · Cited by 79
“In contrast to p53, D133p53 lacks the first 30 residues of the DNA-binding domain encoding the L1 loop and part of the loop-sheet-helix motif that form the structure binding to the major groove of DNA in p53RE (Cho et al., 1994).”
BackgroundEffect of Zn2+ on DNA Recognition and Stability of the p53 DNA-Binding Domain
Duan, J., & Nilsson, L. (2006) · Biochemistry · doi:10.1021/bi0603165 · Cited by 80
Bazan, V., Agnese, V., Corsale, S., Calò, V., Valerio, M. R., Latteri, M. A., Vieni, S., Grassi, N., Cicero, G., Dardanoni, G., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi908 · Cited by 84
“Several structural domains with distinct roles have been identified within these regions: the L2 loop (codons 163–195), required for the folding and stabilization of the central part of the protein; the L3 loop (codons 236–251) and the LSH (L1 loopsheet-ahelix) motif (codons 273–286) within which at least two residues…”
BackgroundJordan, J. J., Inga, A., Conway, K., Edmiston, S., Carey, L. A., Wu, L., & Resnick, M. A. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0442 · Cited by 77
“The DBD of p53 consists of a β-sandwich, which provides a scaffold for two large β-loops, L2 and L3, which are stabilized by a zinc ion and a loop-sheet-helix motif (44, 45).”
BackgroundTumour p53 mutations exhibit promoter selective dominance over wild type p53
Monti, P., Campomenosi, P., Ciribilli, Y., Iannone, R., Inga, A., Abbondandolo, A., Resnick, M. A., & Fronza, G. (2002) · Oncogene · doi:10.1038/sj.onc.1205250 · Cited by 77
“Glycine 245 is a critical residue for overall structure of p53 because it allows the L3 loop to assume a conformation that will not be favoured with an aminoacid containing a side chain (Cho et al., 1994).”
BackgroundProtein and drug interactions in the minor groove of DNA
Morávek, Z., Neidle, S., & Schneider, B. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.5.1182 · Cited by 91
Maiyar, A. C., Huang, A. J., Phu, P. T., Cha, H. H., & Firestone, G. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.21.12414 · Cited by 76
Structures of Protein Complexes by Multidimensional Heteronuclear Magnetic Resonance Spectroscopy
Gronenborn, A. M., & Clore, G. M. (1995) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239509083489 · Cited by 85
“The structure of the core domain complexed to DNA has been solved crystallographically (Cho et al., 1994).”
BackgroundHou, H., Qin, K., Liang, Y., Zhang, C., Liu, D., Jiang, H., Liu, K., Zhu, J., Lv, H., Li, T., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s201513 · Cited by 76
“Disruption of p53’s normal function possibly leads to malignant cell transformation and cancer formation.(1,3,6) Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer (80–85%).”
BackgroundShankar, R., P, G. J., Bajpai, V., et al. (2022) · Environmental Research · doi:10.1016/j.envres.2022.114807 · Cited by 76
Conservation of DNA-binding specificity and oligomerisation properties within the p53 family
Brandt, T., Petrovich, M., Joerger, A. C., & Veprintsev, D. B. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-628 · Cited by 73
“Upon binding to a DNA half-site, two DBDs form a self-complementary protein-protein interface, mediated by residues P177, H178, R181, M243 and G244, which are conserved in vertebrate p53 [40,41].”
BackgroundInfluentialPhosphorylation and hsp90 Binding Mediate Heat Shock Stabilization of p53
Wang, C., & Chen, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m206697200 · Cited by 76
A TPR Motif Cofactor Contributes to p300 Activity in the p53 Response
Demonacos, C., Krstic–Demonacos, M., & Thangue, N. B. L. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00277-5 · Cited by 88
Gonzalez-Fernandez, F., Kaltreider, S. A., Patnaik, B. D., et al. (1998) · Ophthalmology · doi:10.1016/s0161-6420(98)93034-2 · Cited by 76
Keller, D., Zeng, X., Li, X., Kapoor, M., Iordanov, M. S., Taya, Y., Lozano, G., Magun, B. E., & Lu, H. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1023 · Cited by 80
Postel, E. H., Weiss, V. H., Beneken, J., & Kirtane, A. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.14.6892 · Cited by 83
What have animal models taught us about the p53 pathway?
Lozano, G., & Zambetti, G. P. (2005) · The Journal of Pathology · doi:10.1002/path.1704 · Cited by 76
“The crystal structure of the p53 DNA binding domain indicates that this arginine is critical for stabilizing the structure of the DNA binding domain [138].”
BackgroundStructure and Expression of the TREX1 and TREX2 3′→5′ Exonuclease Genes
Mazur, D. J., & Perrino, F. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010051200 · Cited by 75
Bosch, F. X., Ritter, D., Enders, C., Flechtenmacher, C., Abel, U. R., Dietz, A., Hergenhahn, M., & Weidauer, H. (2004) · International Journal of Cancer · doi:10.1002/ijc.11698 · Cited by 83
New insights into Hoogsteen base pairs in DNA duplexes from a structure-based survey
Zhou, H., Hintze, B. J., Kimsey, I. J., Sathyamoorthy, B., Shan, Y., Richardson, J. S., & Al‐Hashimi, H. M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv241 · Cited by 73
“It is interesting to note that constricted C1′–C1′ distances naturally lead to a narrowed minor groove of the bp which can result in favorable electrostatic interactions through minor groove recognition as observed for example with Arg248 in the structure of the p53-DNA complex (17,79).”
BackgroundNorth, S., Pluquet, O., Maurici, D., El Ghissassi, F., & Hainaut, P. (2002) · Molecular Carcinogenesis · doi:10.1002/mc.10038 · Cited by 75
Determination of the drug–DNA binding modes using fluorescence-based assays
Williams, A. K., Dasilva, S. C., Bhatta, A., Rawal, B., Liu, M., & Korobkova, E. A. (2012) · Analytical Biochemistry · doi:10.1016/j.ab.2011.12.041 · Cited by 74
“Thus, a lot of proteins, including tumor suppressors and signal transduction and transcription proteins, exhibit exclusive DNA minor groove binding [42,43].”
BackgroundMutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11
Noll, J. E., Jeffery, J., Al‐Ejeh, F., Kumar, R., Khanna, K. K., Callen, D. F., & Neilsen, P. M. (2011) · Oncogene · doi:10.1038/onc.2011.456 · Cited by 78
30 years and a long way into p53 research
Hainaut, P. L., & Wiman, K. G. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70198-6 · Cited by 87
Autoregulation of Eukaryotic Transcription Factors
Bateman, E. (1998) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(08)60892-2 · Cited by 80
Folding intermediates are involved in genetic diseases?
Bychkova, V. E., & Ptitsyn, O. B. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00004-s · Cited by 75
Venot, C., Maratrat, M., Sierra, V., Conseiller, E., & Debüssche, L. (1999) · Oncogene · doi:10.1038/sj.onc.1202539 · Cited by 88
“…(i) a central core domain responsible for sequence-speci®c DNA binding (amino acid residues 102 ± 292) (Bargonetti et al., 1993; Pavletich et al., 1993; Cho et al., 1994); (ii) a Nterminal transactivation domain responsible for recruitment of transcription machinery (amino acid residues 1 ± 40)…”
BackgroundGudas, J. M., Nguyen, H., Klein, R. C., Katayose, D., Seth, P. K., & Cowan, K. H. (1995) · PubMed · Cited by 81
Mutant TP53 Posttranslational Modifications: Challenges and Opportunities
Nguyen, T.-A., Menendez, D., Resnick, M. A., & Anderson, C. W. (2014) · Human Mutation · doi:10.1002/humu.22506 · Cited by 69
“Among the mutations in this domain, about 30% locate within six “hotspot” residues that are frequent in almost all cancer types [Hollstein et al., 1991; Cho et al., 1994], for example, Arg175, Gly245, Arg248, Arg249, Arg273, and Arg282, but which are not known to be posttranslationally modified.”
Backgroundp53 isoforms - A conspiracy to kidnap p53 tumor suppressor activity?
Marcel, V., & Hainaut, P. L. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8336-3 · Cited by 88
Structural dynamics of the E6AP/UBE3A-E6-p53 enzyme-substrate complex
Sailer, C., Offensperger, F., Julier, A., Kammer, K.-M., Walker‐Gray, R., Gold, M. G., Scheffner, M., & Stengel, F. (2018) · Nature Communications · doi:10.1038/s41467-018-06953-0 · Cited by 91
Imbalance between pro-oxidant and pro-antioxidant functions of zinc in disease
Hao, Q., & Maret, W. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8209 · Cited by 83
“The transcription factor p53 is a tumor suppressor with functions at a critical juncture of signaling pathways that link DNA damage, cell cycle inhibition, and apoptosis. p53 is a zinc protein with a zinc finger in the DNA-binding domain [88].”
Combinatorial gene regulation by eukaryotic transcription factors
Chen, L. (1999) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(99)80007-4 · Cited by 80
“The recent structure determinations of NFAT, STATs and the T-domain [47•] reveal that these proteins, together with p53 [48] and NF-κB [43,44], form a superfamily that uses the Ig module as a scaffold for presenting various secondary structural elements for DNA recognition (Figure 5).”
Backgroundp53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma.
Hirvikoski, P. P., Kumpulainen, E., Virtaniemi, J. A., Johansson, R. T., Haapasalo, H. K., Marin, S., Halonen, P., Helin, H. O., Raitiola, H. S., Pukander, J., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.9.3111 · Cited by 71
p53 and Rb: their cellular roles
Picksley, S. M., & Lane, D. P. (1994) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(94)90056-6 · Cited by 84
Blanden, A. R., Yu, X., Blayney, A. J., Demas, C., Ha, J.-H., Liu, Y., Withers, T., Carpizo, D. R., & Loh, S. N. (2020) · eLife · doi:10.7554/elife.61487 · Cited by 78
“The X-ray crystal structure of DBD (residues 94–312) reveals a b-sandwich with a DNA-binding surface consisting of a loop-sheet-helix motif and two loops (L2 and L3) (Figure 1; Cho et al., 1994).”
BackgroundMelero, R., Rajagopalan, S., Lázaro, M., Joerger, A. C., Brandt, T., Veprintsev, D. B., Lasso, G., Gil, D., Scheres, S. H. W., Carazo, J. M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015520107 · Cited by 64
“These structures show varying dimer-dimer contacts and the overall assembly of the core domains on DNA is radically different from the one described in the first DBD · DNA complex solved (23).”
BackgroundDetection of the p53 response in zebrafish embryos using new monoclonal antibodies
Lee, K.-C., Goh, W. L., Xu, M., Kua, N., Lunny, D. P., Wong, J. S., Coomber, D., Vojtĕsek, B., Lane, E. B., & Lane, D. P. (2007) · Oncogene · doi:10.1038/sj.onc.1210695 · Cited by 73
González, M. V., Pello, M. F., López‐Larrea, C., Suarez, C. M., Menéndez, M., & Coto, E. (1995) · PubMed · Cited by 82
Powell, B. L., Soong, R., Iacopetta, B. J., Seshadri, R., & Smith, D. R. (2000) · PubMed · Cited by 73
Eukaryotic transcription factors
Warren, A. J. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00296-8 · Cited by 73
The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A
Luciani, M. G., Hutchins, J. R. A., Zheleva, D. I., & Hupp, T. R. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3830 · Cited by 79
Aurelio, O. N., Kong, X.-T., Gupta, S., & Stanbridge, E. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.3.770-778.2000 · Cited by 73
“A study of the crystal structure of the sequence-specific DNA binding domain of p53 showed that this domain was susceptible to drastic conformational changes due to single amino acid substitutions (11).”
BackgroundStructure and Mechanism in NF- B/I B Signaling
Huxford, T., Malek, S., & Ghosh, G. (1999) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1999.64.533 · Cited by 87
TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Soussi, T. (2011) · Advances in cancer research · doi:10.1016/b978-0-12-386469-7.00005-0 · Cited by 86
Zinc Oxide Nanoparticles: Green Synthesis and Biomedical Applications
Sadhasivam, S., Shanmugam, M., Umamaheswaran, P. D., Anbazhagan, V., & Anusuya, S. (2020) · Journal of Cluster Science · doi:10.1007/s10876-020-01918-0 · Cited by 79
In vitro analysis of the dominant negative effect of p53 mutants
Chêne, P. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1897 · Cited by 72
Eldar, A., Rozenberg, H., Diskin-Posner, Y., Rohs, R., & Shakked, Z. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt630 · Cited by 72
Modulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies
Martinelli, A. H. S., Lopes, F. C., John, E. B. D. O., Carlini, C. R., & Ligabue‐Braun, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061322 · Cited by 105
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.